These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 7879813)

  • 21. Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Italian Group for Antiemetic Research.
    Support Care Cancer; 2000 May; 8(3):229-32. PubMed ID: 10789965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical studies of oral antiemetic drugs on delayed emesis induced by cancer chemotherapy].
    Sawaguchi K; Yabushita H; Tsukada H; Yamada H; Noguchi M; Nakanishi M
    Gan To Kagaku Ryoho; 1999 Jan; 26(1):117-23. PubMed ID: 9987507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Role of ondansetron in oncology].
    Laplanche A; Gérondeau N
    Bull Cancer; 1993 Jul; 80(7):568-76. PubMed ID: 8204937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [On what indication should serotonin antagonists be used? A retrospective study of the use of ondansetron at an oncologic unit].
    Norum J
    Tidsskr Nor Laegeforen; 1993 Aug; 113(18):2235-8. PubMed ID: 8362385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Antiemetic prophylaxis after laparoscopic cholecystectomy: comparative study of dehydrobenzperidol, metoclopramide, ondansetron and placebo].
    Pertusa V; Bellver J; Marqués A; Onrubia X; Viñals MP; Sanmiguel G; Seller JM; Martínez-Carrasco C
    Rev Esp Anestesiol Reanim; 1996; 43(7):239-42. PubMed ID: 8966351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of delayed emesis caused by chemotherapy.
    Harmon D; O'Brien B
    N Engl J Med; 2000 Sep; 343(12):889; author reply 889-90. PubMed ID: 11001695
    [No Abstract]   [Full Text] [Related]  

  • 27. An overview of ondansetron for chemotherapy-induced nausea and emesis.
    San Angel F
    J Intraven Nurs; 1993; 16(2):84-9. PubMed ID: 8478782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the pharmacoeconomic literature.
    Milne RJ
    Pharmacoeconomics; 1994 Oct; 6(4):337-45. PubMed ID: 10147470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multicenter evaluation of ondansetron use in hospitalized oncology patients.
    Peters MD; Long KS; Patel HS; Reitz JA; Jessen LM; Emhart GC
    Am J Hosp Pharm; 1993 Jun; 50(6):1164-70. PubMed ID: 8517455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative evaluation of the clinical efficacy and safety of ondansetron and metoclopramide in the prophylaxis of emesis induced by cancer chemotherapy regimens including cisplatin.
    Advani SH; Gopal R; Dhar AK; Lal HM; Cooverji ND
    J Assoc Physicians India; 1996 Feb; 44(2):127-30. PubMed ID: 10999066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
    Cunningham RS
    Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Use of metoclopramide for the prevention of vomiting induced by cytostatics].
    Lutyński A; Dwilewicz-Trojaczek J; Rokicka M; Paprocka E; Kuratowska Z
    Nowotwory; 1984; 34(3):237-44. PubMed ID: 6531221
    [No Abstract]   [Full Text] [Related]  

  • 33. Metoclopramide (Reglan).
    Med Lett Drugs Ther; 1982 Jul; 24(614):67-9. PubMed ID: 7087890
    [No Abstract]   [Full Text] [Related]  

  • 34. [Cost-effective treatment with ondansetron].
    Glaxo AS
    Tidsskr Nor Laegeforen; 1993 Aug; 113(20):2602. PubMed ID: 7639831
    [No Abstract]   [Full Text] [Related]  

  • 35. Biotech R&D spend jumps by more than 15.
    Mullard A
    Nat Rev Drug Discov; 2016 Jun; 15(7):447. PubMed ID: 27357013
    [No Abstract]   [Full Text] [Related]  

  • 36. Re-examination of clinical aspects of pharmacoeconomic analysis.
    Rubenstein EB; Elting LS
    Am J Hosp Pharm; 1994 Dec; 51(23):2970-3. PubMed ID: 7879813
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacoeconomic analysis of ondansetron versus metoclopramide for cisplatin-induced nausea and vomiting.
    Zbrozek AS; Cantor SB; Cardenas MP; Hill DP
    Am J Hosp Pharm; 1994 Jun; 51(12):1555-63. PubMed ID: 8092156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of ondansetron and granisetron on chemotherapy-induced emesis in adults: the need for comparative pharmacoeconomic data.
    Hedayati S; Moatti JP; Seitz JF
    Clin Ther; 1994; 16(3):569-80. PubMed ID: 7923321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer.
    Lachaine J; Laurier C; Langleben A; Vaillant L
    Crit Rev Oncol Hematol; 1999 Nov; 32(2):105-12. PubMed ID: 10612010
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacoeconomic analyses: whose perspective counts and costs the most?
    Rubenstein EB; Elting LS
    Am J Hosp Pharm; 1994 Jun; 51(12):1564-9. PubMed ID: 8092157
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.